Skip to main content
OpenTrials

Clinical trial condition

Mantle Cell Lymphoma

Explore clinical trials studying Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

251 public trials 59 recruiting studies
Refine in advanced search Browse all conditions

Mantle Cell Lymphoma trial results

Completed

AMG 319 Lymphoid Malignancy FIH

NCT01300026

Conditions
Cancer, Chronic Disease, Chronic Lymphocytic Leukemia, +33 more
Locations
  • Research Site Hackensack, New Jersey, United States
  • Research Site Durham, North Carolina, United States
  • Research Site Salt Lake City, Utah, United States
View Trial Details
Completed

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

NCT00633594

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Providence Medical Group Terre Haute, Indiana, United States
  • RHHP/ Hope Cancer Center Terre Haute, Indiana, United States
  • St. Louis Cancer Care Chesterfield, Missouri, United States
  • Hematology-Oncology Associates of Northern NJ Morristown, New Jersey, United States
View Trial Details
Completed

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

NCT00607854

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Service d'hématologie - CHU de Besançon Besançon, France
  • Service des maladies du sang - Hôpital Haut-Lévêque - avenue de magellan Bordeaux - Pessac, France
  • Service d'hématologie - CHU Hôtel Dieu Clermont-Ferrand Clermont-Ferrand, France
  • Service de médecine nucléaire - Centre de Lutte contre le Cancer de la Région Auvergne Jean Perrin Clermont-Ferrand, France
View Trial Details
Completed

Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

NCT00786851

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Ospedale SS. Antonio Biagio e Cesare Arrigo Alessandria, Italy
  • Centro diriferimento oncologico Aviano (PN), Italy
  • Ematologia Spedali Civili Brescia, Italy
  • Ematologia Ospedale Businco Cagliari, Italy
View all 17 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

NCT01599949

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Stanford, California, United States
  • Norwalk, Connecticut, United States
View all 56 locations
View Trial Details
Completed

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01410513

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +19 more
Locations
  • Investigational Site Number 840004 Aurora, Colorado, United States
  • Investigational Site Number 840006 Augusta, Georgia, United States
  • Investigational Site Number 840002 Charleston, South Carolina, United States
View Trial Details

Related conditions